BCX 4430 3022 Epetraborole was in development for

Epetraborole was in development for the treatment of infections caused by multidrug-resistant Gram-negative pathogens

13 mg/mL(50 mM)

Osteoporos Int

In platelet physiological responses

Formula: C8H14ClNO2

BCX 4430 3022 Epetraborole was in development forGalidesivir, also known as BCX4430 and Immucillin A, is an antiviral drug and an adenosine analog. Galidesivir was originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. Galidesivir also shows broad spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses,